Latest news and press releases about Lite Strategy, Inc. (LITS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.
Price
| Price | $1.02 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.14 |
| EV / EBITDA | -2.58 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -90.81% |
| Return on Invested Capital | -22.40% |
| Return on Assets | -105.24% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACET · ACRV · HOWL · IMUX · IOBT · NTRB · PMVP
Explore sector: Healthcare · Biotechnology
More sections of LITS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks